Condition
Dermatomyositis (DM)
Total Trials
5
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 4 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Enrolling By Invitation1
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07111065Phase 2RecruitingPrimary
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
NCT07531446Active Not RecruitingPrimary
Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical Parameters
NCT06723106Phase 1Enrolling By Invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06371417Phase 1Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT01151644Phase 4Unknown
Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
Showing all 5 trials